HEMLIBRA

DRUG2 trials

Sponsors

Emory University, Montefiore Medical Center

Conditions

Hemophilia A

Phase 3

Emicizumab PUPs and Nuwiq ITI Study

WithdrawnNCT04030052

Emory UniversityHemophilia A

Start: 2022-02-17End: 2023-01-19Updated: 2024-01-05

Unknown Phase

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

CompletedNCT05248594

Montefiore Medical CenterHemophilia A

Start: 2024-08-01End: 2025-07-18Updated: 2025-09-08

Related Papers

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Blood2023-02-0316 citations

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors

BMJ Open2022-03-017 citations